Metabolomic analysis for first-trimester trisomy 18 detection

Area of Science:

• Biochemistry
• Genetics
• Prenatal Diagnostics

Background:

• Trisomy 18 (Edwards syndrome) is a severe chromosomal abnormality.
• Early and accurate prenatal detection of trisomy 18 is crucial for genetic counseling and management.
• Current screening methods have limitations in sensitivity and specificity.

Purpose of the Study:

• To investigate the utility of nuclear magnetic resonance (NMR)-based metabolomic markers in first-trimester maternal serum for detecting fetal trisomy 18.
• To assess the ability of these markers to differentiate trisomy 18 from euploid pregnancies and trisomy 21.

Main Methods:

• Analysis of maternal serum samples from pregnancies between 11 and 13 weeks 6 days' gestation.
• Inclusion of 30 cases of trisomy 18, 30 cases of trisomy 21, and 114 euploid cases.
• Application of NMR-based metabolomic profiling to identify distinct metabolite patterns.

Main Results:

• Metabolomic markers demonstrated sensitivity for trisomy 18 detection.
• A combination of 2-hydroxybutyrate, glycerol, and maternal age achieved 73.3% sensitivity and 96.6% specificity for trisomy 18 (AUC: 0.92, P < .001).
• Specific metabolites, including trimethylamine, effectively distinguished trisomy 18 from trisomy 21.

Conclusions:

• This study presents the first report on prenatal trisomy 18 detection using metabolomic analysis.
• Preliminary findings indicate that metabolomic markers are sensitive for detecting fetal trisomy 18.
• These markers also show potential in distinguishing trisomy 18 from trisomy 21, offering a novel approach to prenatal screening.